APA

Frias J. P., Nauck M. A., Van J., Kutner M. E., Cui X., Benson C., Urva S., Gimeno R. E., Milicevic Z., Robins D. & Haupt A. (20190129). Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. : Lancet (London, England).

Chicago

Frias Juan Pablo, Nauck Michael A, Van Joanna, Kutner Mark E, Cui Xuewei, Benson Charles, Urva Shweta, Gimeno Ruth E, Milicevic Zvonko, Robins Deborah and Haupt Axel. 20190129. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. : Lancet (London, England).

Harvard

Frias J. P., Nauck M. A., Van J., Kutner M. E., Cui X., Benson C., Urva S., Gimeno R. E., Milicevic Z., Robins D. and Haupt A. (20190129). Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. : Lancet (London, England).

MLA

Frias Juan Pablo, Nauck Michael A, Van Joanna, Kutner Mark E, Cui Xuewei, Benson Charles, Urva Shweta, Gimeno Ruth E, Milicevic Zvonko, Robins Deborah and Haupt Axel. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. : Lancet (London, England). 20190129.